• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

Research Brief on 1-Methyl-3-Piperidinecarboxaldehyde (CAS: 99658-56-7): Recent Advances and Applications

1-Methyl-3-piperidinecarboxaldehyde (CAS: 99658-56-7) is a key intermediate in the synthesis of various bioactive compounds and pharmaceuticals. Recent studies have highlighted its significance in drug discovery, particularly in the development of central nervous system (CNS) agents and antimicrobial compounds. This research brief consolidates the latest findings on its chemical properties, synthetic applications, and potential therapeutic uses, providing a comprehensive overview for researchers in the chemobiological and pharmaceutical fields.

Recent literature reveals that 1-methyl-3-piperidinecarboxaldehyde serves as a versatile building block in organic synthesis. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of novel piperidine-based inhibitors targeting acetylcholinesterase (AChE), a critical enzyme in neurodegenerative diseases like Alzheimer's. The study reported a 40% improvement in yield compared to traditional methods, underscoring its efficiency as a synthetic precursor.

In addition to its role in CNS drug development, 1-methyl-3-piperidinecarboxaldehyde has shown promise in antimicrobial applications. A 2024 paper in Bioorganic & Medicinal Chemistry Letters detailed its incorporation into quaternary ammonium compounds (QACs) with potent activity against multidrug-resistant Staphylococcus aureus (MRSA). The modified QACs exhibited a minimum inhibitory concentration (MIC) of ≤2 μg/mL, suggesting potential for clinical translation.

Mechanistic studies have further elucidated the compound's reactivity. Nuclear magnetic resonance (NMR) and density functional theory (DFT) analyses indicate that the aldehyde group in 1-methyl-3-piperidinecarboxaldehyde facilitates selective nucleophilic additions, enabling stereocontrolled synthesis of complex heterocycles. This property has been leveraged in the production of opioid receptor modulators, as reported in a 2023 ACS Chemical Neuroscience study.

Despite these advances, challenges remain in scaling up production while maintaining enantiomeric purity. Current research focuses on catalytic asymmetric synthesis methods, with recent breakthroughs in chiral auxiliary-assisted reductions achieving >95% ee. Industry reports from Q1 2024 indicate that several pharmaceutical companies are investing in continuous flow chemistry platforms to optimize the manufacturing process for this intermediate.

The safety profile of 1-methyl-3-piperidinecarboxaldehyde has also been reassessed in light of new toxicological data. Revised guidelines from the European Chemicals Agency (ECHA) in 2023 recommend enhanced personal protective equipment (PPE) during handling due to the compound's moderate dermal absorption potential. These updates underscore the importance of balancing synthetic utility with occupational health considerations.

Looking ahead, the integration of 1-methyl-3-piperidinecarboxaldehyde into fragment-based drug discovery (FBDD) libraries appears particularly promising. Its rigid piperidine scaffold and reactive aldehyde group make it an ideal candidate for generating diverse pharmacophores. Computational docking studies predict strong interactions with various biological targets, positioning this compound as a valuable asset in next-generation drug development pipelines.

• 91324-26-4(Ethanone,1-(1,4-dimethyl-3-piperidinyl)-)
• 57401-78-2(3-Ethyl-1-methyl-4-piperidinone)
• 400709-59-3(1-Azabicyclo[2.2.1]heptane-3-carboxaldehyde(9CI))
• 93117-84-1(1-(1-azabicyclo[2.2.2]oct-3-yl)-Ethanone)
• 99175-86-7(Ethanone,1-(5-ethyl-1-methyl-3-piperidinyl)-)
• 917898-69-2(1-(2,2-dimethylpropyl)piperidine-4-carbaldehyde)
• 118371-33-8(Ethanone,1-(1-propyl-3-piperidinyl)-)
• 5176-21-6(1-Azabicyclo[2.2.2]octane-3-carboxaldehyde)
• 91324-25-3(1-(1-Methylpiperidin-3-yl)ethanone)
• 690632-29-2(2,2-dimethyl-3-(4-methylpiperidin-1-yl)propanal)